Immunotherapy and chemo with bacteria-based drug for early stage triple negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether adding an experimental bacteria-based drug (MO-03) to standard immunotherapy and chemotherapy before surgery helps control early-stage triple negative breast cancer. It aims to reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have early-stage triple negative breast cancer, which means your tumor does not have estrogen, progesterone, or HER2 receptors.
- Your cancer is high risk (based on size or lymph node involvement) and has not spread to distant organs.
- You are able to provide a tumor sample from your initial biopsy and from any leftover tissue after surgery.
- You are reasonably healthy and able to perform daily activities (ECOG 0-1).
- You have not had prior chemotherapy, immunotherapy, or breast surgery for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
This trial tests whether giving the immunotherapy drug camrelizumab along with chemotherapy and radiation before surgery can help shrink early-stage triple-negative breast cancer tumors. It aims to improve treatment outcomes for this aggressive but curable cancer.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
Hear when a new Early Stage Triple-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.